CRON:NSD-Cronos Group Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 11.09

Change

+0.16 (+1.46)%

Market Cap

USD 3.93B

Volume

4.57M

Average Target Price

USD 8.67 (-21.85%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+0.17 (+0.51%)

USD12.55B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

+1.19 (+9.58%)

USD3.96B 41.54 454.68
PCRX Pacira BioSciences, Inc

+0.17 (+0.23%)

USD3.20B 25.14 65.69
TLRY Tilray, Inc

+0.39 (+1.98%)

USD3.12B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.05 (-0.45%)

USD1.77B 15.78 14.06
ENDP Endo International plc

-0.06 (-0.84%)

USD1.64B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

+0.53 (+1.81%)

USD1.54B 12.12 7.71
ORGO Organogenesis Holdings Inc

-0.01 (-0.11%)

USD1.21B 456.50 77.95

ETFs Containing CRON

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

+0.38 (+1.92%)

USD0.94B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

+0.59 (+2.50%)

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

+0.27 (+1.51%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.80% 84% B 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.80% 84% B 96% A
Trailing 12 Months  
Capital Gain 35.74% 82% B- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.74% 82% B- 69% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.00% 72% C- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.00% 72% C- 53% F
Risk Return Profile  
Volatility (Standard Deviation) 66.55% 21% F 17% F
Risk Adjusted Return 9.01% 68% D+ 38% F
Market Capitalization 3.93B 96% A 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.08 33% F 29% F
Price/Book Ratio 2.20 78% C+ 58% F
Price / Cash Flow Ratio -30.19 91% A- 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 5.82% 85% B 65% D
Return on Invested Capital -12.00% 65% D 33% F
Return on Assets -5.72% 63% D 31% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.51 42% F 18% F
Short Percent 15.36% 30% F 13% F
Beta 2.09 18% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.